公开(公告)号：US20200181277A1

公开(公告)日：2020-06-11

申请号：US16482747

申请日：2018-02-12

申请人： GENMAB B.V.

发明人： Frank BEURSKENS ,  Marije OVERDIJK ,  Annieck M. DIKS ,  Rob DE JONG ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  C07K16/10

摘要： As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

公开(公告)号：US20190202926A1

公开(公告)日：2019-07-04

申请号：US15780285

申请日：2016-12-01

申请人： GENMAB B.V.

发明人： Frank BEURSKENS ,  Marije OVERDIJK ,  Rob DE JONG ,  David SATIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  A61P35/00 ,  C07K16/30

CPC分类号： C07K16/2878 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/30 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/73 ,  C07K2317/75 ,  C12N15/62

摘要： The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20210238296A1

公开(公告)日：2021-08-05

申请号：US17051205

申请日：2019-05-03

申请人： GENMAB B.V.

发明人： Rob DE JONG ,  Frank BEURSKENS ,  Simone OOSTINDIE ,  Aran Frank LABRIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Bart-Jan DE KREUK

IPC分类号： C07K16/28 ,  A61K45/06

摘要： Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

公开(公告)号：US20220411522A1

公开(公告)日：2022-12-29

申请号：US17684238

申请日：2022-03-01

申请人： GENMAB B.V.

发明人： Frank BEURSKENS ,  Marije OVERDIJK ,  Rob DE JONG ,  David SATIJN ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  C12N15/62

摘要： The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US20220411529A1

公开(公告)日：2022-12-29

申请号：US17774333

申请日：2020-11-06

申请人： GENMAB B.V.

发明人： Rob DE JONG ,  Frank BEURSKENS ,  Gijs ZOM ,  Janine SCHUURMAN ,  Xiaoguang XUE

IPC分类号： C07K16/28

摘要： The invention relates to combination therapy involving two or more antibodies, wherein the Fc regions of the two antibodies have been modified such that hetero-oligomerization between the antibodies is strongly favored over self-oligomerization when antibodies are bound to their corresponding target antigens and such that hetero-oligomerization-independent effector functions of one or both antibodies are eliminated or strongly reduced. The invention also relates to antibodies, compositions, and kits suitable for use in the combination therapy of the invention.

公开(公告)号：US20220332801A1

公开(公告)日：2022-10-20

申请号：US17534712

申请日：2021-11-24

申请人： GENMAB B.V.

发明人： Annemarie KUIPERS ,  Kok VAN KESSEL ,  Frank BEURSKENS ,  Rob DE JONG ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN ,  Jos VAN STRIJP ,  Suzan ROOIJAKKERS

IPC分类号： C07K16/12 ,  A61P31/04

摘要： The present invention relates to antibody molecules that bind to Wall Teichoic Acid (WTA) or Capsular Polysaccharides (CP) such as Capsular Polysaccharides type 5 (CP5). The invention relates in particular to antibody molecules of the IgG isotype having a mutation in the Fc domain that enhances clustering of IgG molecules after target binding. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of infectious diseases using these compositions

公开(公告)号：US20210107988A1

公开(公告)日：2021-04-15

申请号：US16963701

申请日：2019-01-24

申请人： GENMAB B.V.

发明人： Simone OOSTINDIE ,  Andreas HOLLENSTEIN ,  Frank BEURSKENS ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Rob DE JONG

IPC分类号： C07K16/28 ,  A61P35/00

摘要： The present invention relates to combination therapy involving two or more Fc region-containing antigen-binding polypeptides, such as antibodies, wherein the polypeptides have been modified such that hetero-oligomerization between the polypeptides is strongly favored over homo-oligomerization when the polypeptides are bound to their corresponding target antigens. The invention also relates to polypeptides, compositions, kits and devices suitable for use in the combination therapy of the invention.

公开(公告)号：US20190276549A1

公开(公告)日：2019-09-12

申请号：US16345044

申请日：2017-11-01

申请人： GENMAB B.V.

发明人： Rob DE JONG ,  Frank BEURSKENS ,  Marije OVERDIJK ,  Kristin STRUMANE ,  Janine SCHUURMAN ,  Paul PARREN

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61P37/06 ,  A61P31/04 ,  A61P31/12 ,  A61P31/10

摘要： Described herein are polypeptides and antibodies comprising a variant Fc region. The variant Fc region provides for stabilized Fc-Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, while at the same time also having decreased complement-dependent cytotoxicity (CDC) and may also have decreased activation of other effector functions resulting from one or more amino acid modifications in the Fc region.